Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO WCGIC 2020 | Gemcitabine-based chemotherapy after FOLFIRINOX in advanced pancreatic cancer

Rachel Riechelmann • 6 Jul 2020
ESMO WCGIC 2020
Gastrointestinal Cancer Pancreatic Cancer Folfirinox Gemcitabine

Rachel Riechelmann, MD, PhD, of the AC Camargo Cancer Canter, São Paulo, Brazil, highlights the use of gemcitabine-based chemotherapy after FOLFIRINOX in advanced pancreatic cancer as evaluated in a systemic review and meta-analysis. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

More from Rachel Riechelmann

3:31
Incidence of germline variants in young adults with NETs
Rachel Riechelmann • 6 Jul 2020
1:43
GASTHER2: trastuzumab for advanced gastric cancer
Rachel Riechelmann • 6 Jul 2020
2:33
Localized anal cancer in patients with HIV
Rachel Riechelmann • 6 Jul 2020

Related Videos

0:52
DRP-104 with durvalumab in fibrolamellar hepatocellular carcinoma
Marina Baretti • 9 Apr 2024
1:06
The emerging role of cancer vaccines in treating liver cancer
Marina Baretti • 9 Apr 2024
1:33
Peptide vaccines with ICIs for fibrolamellar hepatocellular carcinoma
Marina Baretti • 9 Apr 2024
4:12
PETRA: saruparib in solid tumors with BRCA1/2, PALB2 or RAD51C/D mutations
Timothy Yap • 7 Apr 2024
The content of VJOncology is intended for healthcare professionals